https://www.selleckchem.com/products/kt-474.html
Approximately 5%-10% of the general population respond inadequately to licensed recombinant hepatitis B vaccines. We assessed the immunogenicity and safety of a new HBAI20 vaccine, consisting of a new AI20 adjuvant (20-µg recombinant human IL-2 attached to 20-µg aluminium hydroxide) in combination with HBVaxPro®-10µg. In a double-blinded, randomised, controlled phase 2 trial, 18- to 59-year-old healthy non-responders (titre 10mIU/ml after three or more doses of hepatitis B vaccine) were assigned (31 ratio) to receive either HBAI20 va
Like
Comment
Share
